Evidence mapPaperPMID 41202120Full record

ArticleScience advances2025

Human stem cell-derived β cells expressing an optimized CD155 reduce cytotoxic immune cell function for application in type 1 diabetes.

Matthew E Brown, Jessie M Barra, Marcus R Pina, James Proia, Todd M Brusko, Holger A Russ

Abstract read
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Matthew E BrownDiabetes Institute, University of Florida, Gainesville, FL, USA.ORCID 0000-0001-8230-5243
Jessie M BarraDiabetes Institute, University of Florida, Gainesville, FL, USA.ORCID 0000-0002-6456-9293
Marcus R PinaDiabetes Institute, University of Florida, Gainesville, FL, USA.ORCID 0009-0002-2180-2531
James ProiaDiabetes Institute, University of Florida, Gainesville, FL, USA.ORCID 0009-0004-5454-9821
Todd M BruskoDiabetes Institute, University of Florida, Gainesville, FL, USA.ORCID 0000-0003-2878-9296
Holger A RussDiabetes Institute, University of Florida, Gainesville, FL, USA.ORCID 0000-0001-5117-2927

Funding

Project 3P01AI042288 · NIAID · UNIVERSITY OF FLORIDA · PI Patrick Concannon · 1997 to 2026
$32.9M
The CD226 costimulatory axis in type 1 diabetesR01DK106191 · NIDDK · UNIVERSITY OF FLORIDA · PI Todd Michael Brusko · 2016 to 2026
$4.4M
NIAID NIH HHS P01 AI042288NIDDK NIH HHS R01 DK106191
6 · The paper itself

Abstract

Insulin-producing β cell replacement therapies show promise for treating type 1 diabetes (T1D), but challenges such as donor shortages and immune rejection persist. Stem cell-derived β cells (sBC) provide a renewable source but remain susceptible to immune attack. We engineered human pluripotent stem cells to express either the wild type (WT) or a high-affinity mutant (Mut) variant (rs1058402, G>A; Ala

Indexed as

Cytotoxicity, ImmunologicDiabetes Mellitus, Type 1Insulin-Secreting CellsReceptors, VirusCD8-Positive T-LymphocytesCell DifferentiationHumansKiller Cells, NaturalReceptors, Immunologicpoliovirus receptorReceptors, ImmunologicReceptors, VirusTIGIT protein, human

Identifiers

PMID41202120
PMCPMC13142048

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.